Case history: Aliskiren: the first renin inhibitor for clinical treatment

The first evidence of the existence of renin was presented over 100 years ago. However, the importance of renin and the renin-angiotensin system in the pathogenesis of cardiovascular disease was only fully realized in the 1970s. It was another 20 years before the first inhibitors of renin were avail...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Drug discovery Vol. 7; no. 5; pp. 399 - 410
Main Authors Jensen, Chris, Herold, Peter, Brunner, Hans Rudolf
Format Journal Article
LanguageEnglish
Published 01.05.2008
Online AccessGet full text

Cover

More Information
Summary:The first evidence of the existence of renin was presented over 100 years ago. However, the importance of renin and the renin-angiotensin system in the pathogenesis of cardiovascular disease was only fully realized in the 1970s. It was another 20 years before the first inhibitors of renin were available for clinical research. Here, we describe the discovery and development of aliskiren, an orally active renin inhibitor, which became the first drug in its class to receive regulatory approval. In 2007, it was approved for the treatment of hypertension by the US Food and Drug Administration and the European Medicines Agency.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1474-1784
1474-1776
DOI:10.1038/nrd2550